On the contrary, my dear Dr Watson! [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2019-10-11 09:52  – Posting: # 20684
Views: 325

Hi ElMaestro,

» I remember having heard EU regulators mention preference for method C out of consideration for the type I error.

What? Where?

» But I can't seem to find a presentation from anyone saying so.

Would surprise me if there is any.

» Do you […] have a link or a presentation by a regulator where this was stated?

Nope. The collaborative work about the type I error was removed from the work plan last year (Paola Coppola’s presentation at BioBridges 2018):

[image]


No work plans published this year for both parties due to Brexit. However, there is an unequivocal preference towards methods which show analytically strict control of the TIE.1,2,3 In my experience European regulatory statisticians hate simulation-based methods.

On Wednesday’s workshop I endured a frustrating chat with a statistician of the Austrian agency AGES. Collection of errors and misconceptions:Was like talking to a brick wall.

Yesterday I sent a clarification  e-mail  rant to Thomas Lang (AGES, member of the BSWP). Don’t expect to get a reply.


  1. König F, Wolfsegger M, Jaki T, Schütz H, Wassmer G. Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation. 2014. doi:10.13140/RG.2.1.5190.0967.
  2. König F, Wolfsegger M, Jaki T, Schütz H, Wassmer G. Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation. Trials. 2015; 16(Suppl 2);P218. doi:10.1186/1745-6215-16-S2-P218.
  3. Maurer W, Jones B, Chen Y. Controlling the type 1 error rate in two-stage sequential designs when testing for average bioequivalence. Stat Med. 2018; 37(10): 1587–1607. doi:10.1002/sim.7614.
  4. Kieser M, Rauch G. Two-stage designs for cross-over bioequivalence trials. Stat Med. 2015; 34(16): 2403–16. doi:10.1002/sim.6487.

  1. An all too often overlooked detail: If the interim is at <½N (due to dropouts) one has to use an error-spending function (e.g., Lan and DeMets, Jennison and Turnbull) to control the TIE.
  2. One mio simulations of a narrow grid (step size 2); TIEmax at n1 12 and CV 24%. Approximations by the shifted central t and the non­central t, exact by Owen’s Q. Go for a cup of coffee. The exact method is very slow.
    library(Power2Stage)
    pmethod <- c("shifted", "nct", "exact")
    res     <- data.frame(method = pmethod, TIE = NA, speed = NA)
    for (j in seq_along(pmethod)) {
      start        <- proc.time()[[3]]
      res$TIE[j]   <- power.tsd(method = "B", alpha = rep(0.0294, 2),
                                n1 = 12, CV = 0.24, GMR = 0.95,
                                targetpower = 0.80, theta0 = 1.25,
                                pmethod = pmethod[j], nsims = 1e6)$pBE
      res$speed[j] <- proc.time()[[3]] - start
    }
    res$speed <- signif(res$speed / res$speed[1], 3)
    print(res, row.names = FALSE)
     method      TIE speed
    shifted 0.048959  1.00
        nct 0.048762  1.44
      exact 0.048924 28.40


    With alpha = rep(0.0301, 2):
     method      TIE speed
    shifted 0.050004  1.00
        nct 0.049790  1.44
      exact 0.049693 28.50

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,886 posts in 4,215 threads, 1,366 registered users;
online 9 (1 registered, 8 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 00:24 UTC

The real purpose of the scientific method is to make sure
nature hasn’t misled you into thinking you know something
you actually don’t know.    Robert M. Pirsig

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5